Listed

Bone Biologics Corp: Form 10-Q for the period ended Sep 30, 2021

Filed with the SEC on Nov 15, 2021 and accepted by EDGAR at Nov 15, 2021, 12:38 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2021-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development9 months2021-01-01 to 2021-09-30$47.5kus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2021-07-01 to 2021-09-30−$229.8kus-gaap:OperatingIncomeLoss
Operating income9 months2021-01-01 to 2021-09-30−$642.6kus-gaap:OperatingIncomeLoss
Net income3 months2021-07-01 to 2021-09-30−$509.3kus-gaap:NetIncomeLoss
Net income9 months2021-01-01 to 2021-09-30−$1.4mus-gaap:NetIncomeLoss
Diluted EPS3 months2021-07-01 to 2021-09-30−$0.17us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS9 months2021-01-01 to 2021-09-30−$0.49us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow9 months2021-01-01 to 2021-09-30−$1.0mus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2021-09-30$3.4kus-gaap:CashAndCashEquivalentsAtCarryingValue
Total assetsAt period end2021-09-30$52.4kus-gaap:Assets
Total liabilitiesAt period end2021-09-30$15.2mus-gaap:Liabilities
Shareholders' equityAt period end2021-09-30−$15.1mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001493152-21-028429. Last ingested by Listed: Nov 11, 2026, 03:46 ET. Listed shows no prices and gives no investment advice.